Journal Article Ppublish 6 citations
PubMed: 38699562 DOI: 10.1007/s11901-024-00652-9
Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B.
Curr Hepatol Rep 23(2):241-252
Authors: Harish Gopalakrishna, Marc G Ghany
Affiliations
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 9B-16, Bethesda, MD 20892-1800, USA.
Abstract
Purpose of Review
Advancements in our understanding of the hepatitis B viral (HBV) life cycle have paved the way for novel approaches to treat HBV infection. This review summarizes the various strategies being pursued to achieve a functional cure, defined as loss of hepatitis B surface antigen (HBsAg) and absence of viral replication 6 months off-therapy.
Recent Findings
Direct acting antiviral, host targeting antiviral, and immunological approaches are in various stages of development as treatment for chronic HBV infection.
Summary
Novel treatments are being developed in pursuit of a cure for HBV. Current evidence suggests a single therapeutic agent alone may be insufficient, necessitating the need for combination therapy targeting HBV and the host immune response. Ongoing research focused on identifying the best therapeutic combination holds promise in achieving functional cure for HBV.
MeSH
Infections, Therapeutics, Hepatitis, Chronic, Hepatitis B Surface Antigens, Hepatitis B, Chronic
Cited by
- Hepatitis B virus genotype distribution and mutation patterns: Insights and clinical implications for hepatitis B virus positive patients. World J Exp Med, 2025
- Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates. J Nanobiotechnology, 2024
- Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis. Hepatol Int, 2025